.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
US Army
McKesson
Mallinckrodt
Baxter
Novartis
Julphar
AstraZeneca
Cipla
Queensland Health

Generated: July 28, 2017

DrugPatentWatch Database Preview

Janssen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?

JANSSEN PHARMS has fifty-six approved drugs.

There are thirty-seven US patents protecting JANSSEN PHARMS drugs and there have been three Paragraph IV challenges on JANSSEN PHARMS drugs in the past three years.

There are seven hundred and seventy-eight patent family members on JANSSEN PHARMS drugs in fifty-seven countries.

Summary for Applicant: Janssen Pharms

Patents:37
Tradenames:54
Ingredients:34
NDAs:56
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVOKANA
canagliflozin
TABLET;ORAL204042-002Mar 29, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-001Oct 29, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003RXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-001Jul 31, 2009RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Janssen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
levofloxacin
INJECTABLE;INJECTION020635-002Dec 20, 1996► Subscribe► Subscribe
Janssen Pharms
TOPAMAX
topiramate
TABLET;ORAL020505-003Dec 24, 1996► Subscribe► Subscribe
Janssen Pharms
DURAGESIC-75
fentanyl
FILM, EXTENDED RELEASE;TRANSDERMAL019813-002Aug 7, 1990► Subscribe► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-007Jan 27, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JANSSEN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
canagliflozin
Tablets100 mg and 300 mg
INVOKANA
3/29/2017
canagliflozin andmetforminhydrochloride
Tablets50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg
INVOKAMET
3/29/2017
rivaroxaban
Tablets10 mg, 15 mg, and 20 mg
XARELTO
7/1/2015
itraconazole
Oral Solution10 mg/mL
SPORANOX
5/3/2013
levofloxacin
Oral Solution25 mg/mL
LEVAQUIN
7/30/2009
norelgestromin and ethinyl estradiol
Transdermal System0.15 mg/0.02 mg per 24 hours
ORTHO EVRA
3/22/2007
galantamine hydrobromide
Extended-release Capsules16 mg and 24 mg
RAZADYNE ER
3/11/2006
galantamine hydrobromide
Extended-release Capsules8 mg
RAZADYNE ER
3/2/2006
almotriptan malate
Tablets6.25 mg and 12.5 mg
AXERT
12/8/2005
topiramate
Tablets50 mg
TOPAMAX
9/8/2005
topiramate
Capsules15 mg and 25 mg
TOPAMAX SPRINKLE
9/7/2005
methylphenidate hydrochloride
Extended-release Tablets18 mg*, 27 mg, 36 mg and 54 mg
CONCERTA
7/19/2005
metformin hydrochloride
Extended-release Tablets18 mg, 27 mg, 36 mg and 54 mg
CONCERTA
7/19/2005
risperidone
Orally Disintegrating Tablets0.25 mg
RISPERDAL
4/11/2005
risperidone
Orally Disintegrating Tablets3 mg and 4 mg
RISPERDAL
3/23/2005
galantamine hydrobromide
Tablets4 mg, 8 mg and 12 mg
RAZADYNE
2/28/2005
topiramate
Tablets25 mg, 100 mg and 200 mg
TOPAMAX
12/26/2001

Non-Orange Book Patents for Janssen Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,129,220Substituted indole-O-glucosides► Subscribe
8,323,691Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms► Subscribe
7,482,330Substituted fused heterocyclic C-glycosides► Subscribe
8,129,378Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
6,696,091 Pharmaceutical composition of topiramate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen Pharms Drugs

Country Document Number Estimated Expiration
Argentina008237► Subscribe
Brazil9908488► Subscribe
China1209098► Subscribe
Norway20006007► Subscribe
Russian Federation2379036► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.



Supplementary Protection Certificates for Janssen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00050Denmark► Subscribe
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
0370Netherlands► Subscribe
C/GB98/013United Kingdom► SubscribePRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
2016 00016Denmark► SubscribePRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Covington
Chubb
Harvard Business School
Federal Trade Commission
Citi
Queensland Health
Mallinckrodt
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot